Literature DB >> 7914719

Assay of the c-erbB-2 oncogene encoded protein by ELISA and immunocytochemistry in human breast cancer.

A Nugent1, J Gallagher, J Dolan, N O'Higgins, M J Duffy.   

Abstract

The c-erbB-2 gene is amplified in a wide variety of different adenocarcinomas. Generally, gene amplification correlates with increased expression of the c-erbB-2 oncoprotein. Previous assays for the c-erbB-2 oncoprotein have been qualitative or semi-quantitative. In this investigation using human breast cancers, c-erbB-2 oncoprotein levels as measured by enzyme-linked immunosorbent assay (ELISA) correlated significantly with semi-quantitation by immunocytochemistry (r = 0.843, P < 0.0001, n = 97). The cut-off point for the ELISA which gave the strongest agreement with immunocytochemistry was 15 units/micrograms protein. It is concluded that detection of c-erbB-2 oncoprotein by ELISA is quantitative and objective.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7914719     DOI: 10.1177/000456329403100210

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  3 in total

1.  Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue.

Authors:  M Diez; M Pollán; M Maestro; A Torres; D Ortega; A Gómez; A Sánchez; F Hernando; J L Balibrea
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA).

Authors:  Maria D Corte; Juan A Rodil; Julio Vázquez; Lucia García; Juan C Rodríguez; Miguel Bongera; José C Fernández; Luis O González; Ma Luz Lamelas; Maite Allende; José L García-Muñiz; Antonio Fueyo; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

3.  Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis.

Authors:  P Pfeiffer; E Nexø; S M Bentzen; P P Clausen; K Andersen; C Rose
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.